Two years after a radical change that brought India's patent laws into line with international trading rules, the country's drug makers are taking a new direction. Apoorva Mandavilli reports.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Related links
Related links
Related links in Nature Research
Indian generics companies go on spending spree
Indian law could choke cheap drug supply
Related external links
Biopharmaceutical and Biotechnology Company
Dr Reddy’s Laboratories: Global pharmaceutical company, India
Rights and permissions
About this article
Cite this article
Reinventing an industry. Nature 445, 138–139 (2007). https://doi.org/10.1038/445138a
Published:
Issue Date:
DOI: https://doi.org/10.1038/445138a
This article is cited by
-
Michigan lab axed as Pfizer cuts costs
Nature (2007)
